Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Subscribe To Our Newsletter & Stay Updated
